BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25916286)

  • 1. [Clinical and prognostic analysis of 30 cases of primary central nervous system lymphoma].
    She C; Tan L; Li P; Ma L; Li W
    Zhonghua Xue Ye Xue Za Zhi; 2015 Apr; 36(4):282-5. PubMed ID: 25916286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
    Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Different treatment regimens for primary central nervous system lymphoma:based on SEER database].
    Yang CW; Ren XH; Jiang HH; Li MX; Zhao XZ; Zhu QH; Cui Y; Lin S
    Zhonghua Wai Ke Za Zhi; 2021 Jan; 59(1):52-58. PubMed ID: 33412634
    [No Abstract]   [Full Text] [Related]  

  • 4. Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience.
    Chanswangphuwana C; Rojnuckarin P; Cherdchoo N; Raiyawa T; Uaprasert N
    Hematology; 2018 Aug; 23(7):385-390. PubMed ID: 29256330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics, Surgical Outcomes, and Prognostic Factors of Intracranial Primary Central Nervous System Lymphoma.
    Ouyang T; Wang L; Zhang N; Zhang Z; Xiong Y; Li M; Hong T
    World Neurosurg; 2020 Jul; 139():e508-e516. PubMed ID: 32311566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.
    Hirono S; Iwadate Y; Higuchi Y; Serizawa T; Nagano O; Matsutani T; Saeki N
    J Neurooncol; 2015 Jun; 123(2):237-44. PubMed ID: 25911295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of radiation therapy in primary central nervous system lymphoma : KROG 14-20 Collaborative Study of Brain and Lymphoma Committee.
    Koh HK; Kim IH; Kim TM; Lim DH; Oh D; Cho JH; Kim WC; Kim JH; Chung WK; Jeong BK; Kang KM; Hong S; Suh CO; Kim IA
    J Neurooncol; 2017 Dec; 135(3):629-638. PubMed ID: 28939931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcome and prognostic factors in PCNSL.
    Niparuck P; Boonsakan P; Sutthippingkiat T; Pukiat S; Chantrathammachart P; Phusanti S; Boonyawat K; Puavilai T; Angchaisuksiri P; Ungkanont A; Chuncharunee S; Atichartakarn V
    Diagn Pathol; 2019 Jun; 14(1):56. PubMed ID: 31189479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
    J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of surgical resection in primary central nervous system lymphoma: a single-center retrospective analysis of 70 patients.
    Wu S; Wang J; Liu W; Hu F; Zhao K; Jiang W; Lei T; Shu K
    BMC Neurol; 2021 May; 21(1):190. PubMed ID: 33975554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of the Clinical Characteristics and Prognostic Factors of 31 Cases of Primary Central Nervous System Lymphoma].
    Fu L; Chen L; Wei N; Huang DY; Shen J; Wang JS; Wang YN; Cui H; Yang LZ; Wang Z
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1061-5. PubMed ID: 27531775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT3 Activation Is Associated with Interleukin-10 Expression and Survival in Primary Central Nervous System Lymphoma.
    Yang X; Wang Y; Sun X; Bai X; Cui Q; Zhu H; Qian J; Chen Y; Sun S; Ji N; Liu Y
    World Neurosurg; 2020 Feb; 134():e1077-e1084. PubMed ID: 31778838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
    Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
    [No Abstract]   [Full Text] [Related]  

  • 15. Results of primary central nervous system lymphoma treated by radiation and chemotherapy: retrospective analysis of twelve institutions in the Tokai District of Japan, 1995-1999.
    Kawamura T; Ishiguchi T; Shibamoto Y; Ogino H; Ishihara S; Yamada T; Katada K; Suzuki K; Suzuki H; Mimura M
    Radiat Med; 2006 Jan; 24(1):9-16. PubMed ID: 16715656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
    Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
    Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and treatment efficacy in patients with primary diffuse large B-cell lymphoma of the bone: single institute experience over 11 years.
    Liu YC; Gau JP; Yu YB; Hong YC; Yen CC; Liu CY; Chao TC; Hsiao LT; Liu JH; Chiou TJ; Tzeng CH
    Intern Med; 2014; 53(2):95-101. PubMed ID: 24429447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
    Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
    Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
    DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
    Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide.
    Welch MR; Sauter CS; Matasar MJ; Faivre G; Weaver SA; Moskowitz CH; Omuro AM
    Leuk Lymphoma; 2015 Feb; 56(2):361-7. PubMed ID: 24745937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.